Alpha Centric Advisors LLC Apellis Pharmaceuticals, Inc. Transaction History
Alpha Centric Advisors LLC
- $118 Million
- Q3 2024
A detailed history of Alpha Centric Advisors LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 47,500 shares of APLS stock, worth $1.57 Million. This represents 1.16% of its overall portfolio holdings.
Number of Shares
47,500Holding current value
$1.57 Million% of portfolio
1.16%Shares
4 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$516 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$394 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$368 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$325 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$192 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.64B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...